Program Overview
Target Audience
Commercial Support Acknowledgement
Educational Objectives
Program Faculty
Dates/Cities
Schedule for all Programs
Accreditation Statement
Credit Designation Statement
Disclosure of Conflicts of Interest
Sunshine Act
The treatment of millions of people in the United States with hepatitis C virus (HCV) infection is constantly changing and rapidly improving. With increasing numbers of treatment options available, health care providers now face complex choices regarding the management of each patient with chronic HCV infection. While these options provide the opportunity for a sustained virologic response (SVR) in many patients and can significantly reduce morbidity and mortality from the consequences of untreated HCV infection, they also lead to new clinical challenges, as it is not always possible for clinicians to keep up with the flood of new information they need to be able to provide the best possible care for each patient, including those with cirrhosis, previous treatment failure, chronic kidney disease, or HIV/HCV co-infection.
The HCV in 2015 program has been designed to help clinicians stay up-to-date on the rapidly changing developments in the treatment of patients with chronic HCV infection. These two-hour programs will feature two national-level faculty members who will present and analyze key controversies in HCV patient care. By applying key clinical trial data to actual patient scenarios, the case-based format will provide the audience with enhanced knowledge needed to resolve professional practice gaps in the treatment of patients with HCV infection, which should result in more appropriate and individualized therapy and ultimately to the reduction in morbidity and mortality in this large patient population.
This activity is intended for physicians, physician assistants, advanced practice nurses, and other health care professionals actively involved in the treatment and management of patients with HCV-infection. It is tuition-free and there are no prerequisites.
This activity is supported by an unrestricted educational grant by Gilead Sciences Medical Affairs.
Upon completion of the activity, participants should be able to:
Utilize current standards and guidelines for the management of patients with CHC
| Nezam H. Afdhal, MD Professor of Medicine Harvard Medical School Chief of Hepatology, Director of Liver Center Beth Israel Deaconess Medical Center Boston, Massachusetts |
Maurizio Bonacini, MD Director, HIV-Liver Clinic Department of Transplantation California Pacific Medical Center San Francisco, California |
|
Lennox Jeffers, MD Chief of Hepatology Miami VA Medical Center Associate Chief Center for Liver Disease Professor of Medicine University of Miami's School of Medicine Miami, Florida |
Sammy Saab, MD Professor of Medicine and Surgery The Pfleger Liver Institute David Geffen School of Medicine University of California, Los Angeles Los Angeles, California |
|
Mark Sulkowski, MD Professor of Medicine and Medical Director Viral Hepatitis Center Johns Hopkins University School of Medicine Baltimore, Maryland |
John M. Vierling, MD Professor of Medicine Professor of Surgery Chief of Hepatology Director of Advanced Liver Therapies St. Luke's Hospital, Director of Baylor Liver Health Houston, Texas |
|
Thursday, August 27, 2015 Chicago, IL |
Wednesday, September 2, 2015 Baltimore, MD |
|
Wednesday, September 2, 2015 Los Angeles, CA |
Thursday, September 3, 2015 New York, NY |
|
Tuesday, September 8, 2015 Boston, MA |
Thursday, September 10, 2015 San Francisco, CA |
|
Tuesday, September 15, 2015 Miami, FL |
Wednesday, September 16, 2015 Houston, TX |
6:00 - 6:30 PM Check-in/Walk-in Registration
6:30 - 8:30 PM Program and Q&A
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and ViralEd, Inc. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Postgraduate Institute for Medicine designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity
As of August 1, 2013, pharmaceutical companies are required by the open payments act (AKA Sunshine Act) to account for certain transfers of value provided to physicians. The federal guidance for the Sunshine Act provides exceptions for CME expenses that meet certain criteria. We believe the program to which you are invited meets these exceptions, and therefore we will not be collecting, nor reporting, any information gathered from this program. If federal guidance is further clarified in the future, we will then provide that information to the supporting pharmaceutical companies to the best of our ability.
|
|
 |
